🎤 Upcoming Biotech Conferences
Loading conferences...
Free public preview
Track obesity and metabolic disease catalysts with approval-probability scores and free alerts.
Obesity & Metabolic Biotech Pipeline: Weight Loss and Diabetes Drugs
Every obesity and metabolic disease program BioRadar tracks across 7 public biotech companies — drug candidates, trial phases and upcoming FDA decisions. Updated automatically.
BioRadar is tracking 20 obesity and metabolic disease drug programs across 7 public companies. The most active companies by program count are CORT, VKTX, GILD, BHVN, BIIB.
20Drug programs
7Companies
1In Phase 3
0Upcoming FDA dates
Companies with obesity and metabolic disease programs
Phase 3 obesity & metabolic programs (1)
| Ticker | Drug | Indication |
|---|---|---|
| VKTX | VK2735 | Weight Loss |
Phase 2 obesity & metabolic programs (8)
| Ticker | Drug | Indication |
|---|---|---|
| BHVN | taldefgrobep alfa | Obesity |
| BIIB | RTA 901 | Diabetic Peripheral Neuropathic Pain |
| CORT | Miricorilant (Cohort A) | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorlilant | Antipsychotic-induced Weight Gain (AIWG) |
| CORT | Miricorilant (Cohort B) | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant | Antipsychotic-induced Weight Gain (AIWG) |
| VERU | Semaglutide (Wegovy) weekly injection | Obesity & Overweight |
| VKTX | VK2809 | NASH - Nonalcoholic Steatohepatitis |
Phase 1 obesity & metabolic programs (11)
| Ticker | Drug | Indication |
|---|---|---|
| CORT | CORT118335 | Antipsychotic-induced Weight Gain |
| CORT | Olanzapine | Antipsychotic-induced Weight Gain |
| CORT | Fluvoxamine | Antipsychotic Induced Weight Gain |
| CORT | Miricorilant 150 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 50 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 10 mg | Nonalcoholic Steatohepatitis (NASH) |
| CORT | Miricorilant 100 mg | Nonalcoholic Steatohepatitis (NASH) |
| GILD | Omeprazole | Weight Management |
| GILD | GS-4571 | Weight Management |
| SPRO | Tebipenem Pivoxil Hydrobromide | Diabetes |
| VKTX | VK2735 Drug | Weight Loss |
Track obesity and metabolic disease catalysts before they hit
BioRadar scores every upcoming FDA decision with an AI Probability of Approval, tracks cash runway and dilution risk, and sends free email alerts. Build a obesity and metabolic disease watchlist in minutes.
Start free →
Data: ClinicalTrials.gov, SEC & FDA filings • Informational only, not investment advice. • All biotech stocks A–Z →